drugset / Trial / NCT00307970

Impact of Anti-static Chamber/Mask

NCT00307970

Phase 4 Completed 12 enrolled University of Florida GlaxoSmithKline · collab
RandomizedCrossoverOpen-labelTreatment

Summary

To compare lung delivery of fluticasone propionate delivered by HFA-pMDI, using a conventional polycarbonate of anti-static chamber/mask in a randomized crossover design in 1-6 year old children. Hypothesis: Anti-static chamber/mask would increase the amount of inhaled corticosteroid delivered to young children who passively inhale and cannot breath hold.

Timeline

Start
2003-04
Primary completion
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 110 ug Inhaled

Indications